Quote:

---

I have believed for years that Long-Covid will be an example of Leronlimabs effectiveness...at putting the pieces back together...in spite of its back-burner status.

---

The lack of funds combined with the FDA not understanding leronlimab's mechanisms of action and Long Covid's erratic symptomology is why it was set aside. When we get revenue Long Covid and ME/CFS need to be pursued.